Cambridge Nutritional Sciences PLC (CNSL)
Industry Medical Instruments & Supplies
This stock can be held in an Investment ISA, SIPP and Investment Account
Sell
1.80p
Buy
2.10p
-0.05p (-2.56%)
Prices updated at 16 Dec 2025, 15:04 GMT
| Prices minimum 15 mins delay
Prices in GBX
Omega Diagnostics Group PLC provides in-vitro diagnostics (IVD) products for use in hospitals, blood banks, clinics and laboratories and specializes in the areas of allergy and autoimmune, food intolerance and infectious diseases.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Income statement
Year | 2024 | 2025 |
|---|---|---|
| 10m | 8m | |
| 6m | 5m | |
| -535,000 | -395,000 | |
| -5.47 | -4.74 | |
| -328,000 | 2m | |
| -73,000 | 2m | |
| Sales, General and administrative | 7m | 6m |
| Interest expenses | 22,000 | 17,000 |
| Provision for income taxes | -417,000 | - |
| Operating expenses | 7m | 6m |
| Income before taxes | -745,000 | 2m |
| Net income available to common shareholders | -328,000 | 2m |
| 0.001 | 0.006 | |
| Net interest income | 28,000 | 130,000 |
| Advertising and promotion | - | - |
| Net investment income, net | - | - |
| Realised capital gains (losses), net | - | - |
| Total benefits, claims and expenses | - | - |
| Earnings per share (diluted) | 0.001 | 0.006 |
| Free cash flow per share | 0.0012 | -0.0018 |
| Book value/share | 0.0401 | 0.0479 |
| Debt equity ratio | 0.002582 | 0.011044 |
Balance sheet
Year | 2024 | 2025 |
|---|---|---|
| Current assets | 8m | 8m |
| Current liabilities | 2m | 2m |
| Total capital | 10m | 11m |
| Total debt | 148,000 | 349,000 |
| Total equity | 10m | 11m |
| Total non current liabilities | - | - |
| Loans | - | - |
| Total assets | 14m | 14m |
| Total liabilities | - | - |
| Cash and cash equivalents | 3m | 5m |
| Common stock | 238m | 238m |
Cash flow
Year | 2024 | 2025 |
|---|---|---|
| Cash at beginning of period | 5m | 3m |
| Cash dividends paid | - | - |
| 548,000 | -439,000 | |
| Investments (gains) losses | -3m | 2m |
| 3m | 5m | |
| Net income | - | - |
| 607,000 | -57,000 | |
| -59,000 | -382,000 |
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.
